Plain-English translation of NCT02899299 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Mesothelioma research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial examined whether a combination of two immunotherapy drugs called and worked better than a standard chemotherapy combination ( with or ) for treating pleural mesothelioma, a serious cancer of the lung lining. About 605 patients were randomly assigned to receive one treatment or the other to compare how well each worked and how well patients tolerated the side effects.
Pleural mesothelioma is a difficult-to-treat cancer, and the standard chemotherapy approach has limited success. Researchers wanted to see if this newer immunotherapy medication approach could offer patients a better chance of survival and a better quality of life.
Participants were randomly assigned to receive either the new immunotherapy combination or the standard chemotherapy combination. They visited the clinic regularly to receive their assigned treatment, have blood tests performed, and be monitored for how well the treatment worked and what side effects they experienced. The trial followed participants over time to compare survival rates and quality of life outcomes between the two treatment groups.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
United States